摘要
目的探讨不同方案经肝动脉化疗栓塞术(TACE)治疗肝癌的临床疗效,并总结护理经验。方法将40例行TACE原发性肝癌患者随机分为对照组和观察组,各20例。对照组化学治疗(简称化疗)方案为5-氟尿嘧啶+多柔比星+顺铂,观察组为5-氟尿嘧啶+多柔比星+洛铂,同时两组患者均给予针对性的围手术期护理。结果观察组患者总有效率为65.00%,显著高于对照组的45.00%(P<0.05);观察组治疗后卡氏生活质量评分(KPS评分)为(8.56±9.97)分,高于对照组的(71.83±10.12)分(P<0.05)。两组患者不良反应发生率均为85.00%,差异不明显(P>0.05)。结论加用洛铂的TACE能显著提高原发性肝癌总体疗效,与传统方案相比,不良反应发生率未见明显增加,适当的护理能保证治疗的顺利进行。
Objective To explore the clinical effects of different regimens by transcatheter arterial chemoembolization ( TACE ) for treating hepatic cancer and to summarize the nursing experience. Methods 40 cases of hepatic cancer treated by TACE were randomly divided into the control group and the observation group, 20 cases in each group. The chemotherapeutic regimen in the control group was 5-fluorouracil plus doxorubicin plus cisplatin, while which in the observation group was 5-fluorouracil plus doxorubicin plus lobaplatin. At the same time, the two groups were given the targeted perioperative nursing. The total effective rate, KPS score and the incidence of ad-verse reactions were compared between the two groups. Results The total effective rate of the observation group was 65. 00%, which was significantly higher than 45. 00% in the control group, the difference was statistically significant ( P 〈 0. 05 );the KPS scores after treatment in the observation group were ( 8. 56 ± 9. 97 ) points, which were higher than ( 71. 83 ± 10. 12 ) points in the control group, the difference was statistically significant ( P 〈 0. 05 ) . The occurrence rate of adverse reactions after treatment in the two groups was 85. 00% with no significant difference ( P 〉 0. 05 ) . Conclusion TACE adding lobaplatin can significantly increase the total effect for treating primary hepatic cancer, compared with the traditional regimen, the occurrence rate of adverse reactions shows no obvious in-crease. the proper nursing can ensure TACE to be smoothly conducted.
出处
《中国药业》
CAS
2015年第9期66-67,共2页
China Pharmaceuticals
关键词
经肝动脉化疗栓塞术
原发性肝癌
洛铂
护理
transcatheter arterial chemoembolization
primary liver cancer
lobaplatin
nursing care